[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL155183A0 - Pharmaceutical compositions containing oxapenem-3-carboxylic acids - Google Patents

Pharmaceutical compositions containing oxapenem-3-carboxylic acids

Info

Publication number
IL155183A0
IL155183A0 IL15518301A IL15518301A IL155183A0 IL 155183 A0 IL155183 A0 IL 155183A0 IL 15518301 A IL15518301 A IL 15518301A IL 15518301 A IL15518301 A IL 15518301A IL 155183 A0 IL155183 A0 IL 155183A0
Authority
IL
Israel
Prior art keywords
oxapenem
sub
pharmaceutical compositions
carboxylic acids
compositions containing
Prior art date
Application number
IL15518301A
Other languages
English (en)
Original Assignee
Amura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00309207A external-priority patent/EP1199077A1/de
Priority claimed from GB0105766A external-priority patent/GB0105766D0/en
Priority claimed from GB0119165A external-priority patent/GB2369358A/en
Application filed by Amura Ltd filed Critical Amura Ltd
Publication of IL155183A0 publication Critical patent/IL155183A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D503/00Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL15518301A 2000-10-19 2001-10-11 Pharmaceutical compositions containing oxapenem-3-carboxylic acids IL155183A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00309207A EP1199077A1 (de) 2000-10-19 2000-10-19 Stabilisierte Oxapenem-3-carbonsäure enthaltende Arzneimittel durch Gefriergetrocknen mit pharmazeutischen Trägern
GB0105766A GB0105766D0 (en) 2001-03-08 2001-03-08 Orally active compounds
GB0119165A GB2369358A (en) 2000-10-19 2001-08-06 Oxapenems and pharmaceutical compositions thereof
PCT/GB2001/004527 WO2002032423A1 (en) 2000-10-19 2001-10-11 Pharmaceutical compositions containing oxapenem-3-carboxylic acids

Publications (1)

Publication Number Publication Date
IL155183A0 true IL155183A0 (en) 2003-11-23

Family

ID=27223564

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15518301A IL155183A0 (en) 2000-10-19 2001-10-11 Pharmaceutical compositions containing oxapenem-3-carboxylic acids

Country Status (18)

Country Link
US (1) US7247622B2 (de)
EP (1) EP1326607B1 (de)
JP (1) JP4283535B2 (de)
CN (1) CN1219512C (de)
AT (1) ATE401884T1 (de)
AU (2) AU9400401A (de)
BR (1) BR0114762A (de)
CA (1) CA2425314C (de)
CZ (1) CZ296089B6 (de)
DE (1) DE60135002D1 (de)
DK (1) DK1326607T3 (de)
ES (1) ES2310561T3 (de)
HK (1) HK1053793A1 (de)
HU (1) HUP0500956A3 (de)
IL (1) IL155183A0 (de)
MX (1) MXPA03003280A (de)
PL (1) PL206257B1 (de)
WO (1) WO2002032423A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition
KR20120101015A (ko) 2009-10-23 2012-09-12 다우 코닝 코포레이션 친수성-개질된 실리콘 조성물
US9689021B2 (en) * 2011-10-14 2017-06-27 Université de Liège Method for measuring beta-lactam antibiotics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2045236A (en) 1979-03-26 1980-10-29 Hoechst Uk Ltd Oxapenem derivatives
US4293555A (en) 1979-04-17 1981-10-06 Merck & Co., Inc. 6- and 6,6-Disubstituted-2-substituted-oxapen-2-em-3-carboxylic acids
DE3725375A1 (de) 1987-07-31 1989-02-09 Bayer Ag Stabile oxapenem-3-carbonsaeuren
DE3833693A1 (de) * 1988-10-04 1990-04-05 Bayer Ag Stabile oxapenem-3-carbonsaeuren und ihre verwendung als ss-lactamasehemmer
DE4027928A1 (de) 1990-09-04 1992-03-05 Bayer Ag Neue 2-tert.substituierte methyl-oxapenem-3-carbonsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung
DE4142423A1 (de) 1991-12-20 1993-06-24 Pfaendler Hans Rudolf ((ls)-hydroxyalkyl)oxapenem-3-carbonsaeuren und ihre verwendung als betalactamasehemmer
WO1996038450A1 (en) 1995-05-31 1996-12-05 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
EP1199077A1 (de) * 2000-10-19 2002-04-24 Amura Limited Stabilisierte Oxapenem-3-carbonsäure enthaltende Arzneimittel durch Gefriergetrocknen mit pharmazeutischen Trägern
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition

Also Published As

Publication number Publication date
PL361312A1 (en) 2004-10-04
EP1326607B1 (de) 2008-07-23
WO2002032423A1 (en) 2002-04-25
DE60135002D1 (de) 2008-09-04
ATE401884T1 (de) 2008-08-15
HUP0500956A2 (en) 2006-05-29
EP1326607A1 (de) 2003-07-16
ES2310561T3 (es) 2009-01-16
HK1053793A1 (en) 2003-11-07
US7247622B2 (en) 2007-07-24
CN1469744A (zh) 2004-01-21
CN1219512C (zh) 2005-09-21
JP4283535B2 (ja) 2009-06-24
JP2004511519A (ja) 2004-04-15
MXPA03003280A (es) 2004-12-13
US20040067929A1 (en) 2004-04-08
AU9400401A (en) 2002-04-29
HUP0500956A3 (en) 2013-01-28
CZ296089B6 (cs) 2006-01-11
CZ20031214A3 (cs) 2003-10-15
AU2001294004B2 (en) 2007-04-26
BR0114762A (pt) 2003-10-07
DK1326607T3 (da) 2008-11-17
CA2425314C (en) 2009-04-28
CA2425314A1 (en) 2002-04-25
PL206257B1 (pl) 2010-07-30

Similar Documents

Publication Publication Date Title
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
WO2002074726A3 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
GB0123589D0 (en) Organic compounds
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
EP1018514A4 (de) Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
WO2002076918A8 (en) NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
EP1279665A3 (de) Ein Verfahren zur Herstellung von Perindopril, analogen Verbindungen dazu sowie Salzen davon unter Verwendung von 2,5-Dioxooxazolidin-Zwischenprodukten
DE69921151D1 (de) Fluorszierende marker
EA200100090A3 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
AU2002215930A1 (en) A process for the preparation of bis-benzazolyl compounds
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
AU9400401A (en) Pharmaceutical compositions containing oxapenem-3-carboxylic acids
HK1064673A1 (en) Fused-polycyclic compounds
AU5257901A (en) Hydrates and crystals of a neuraminic acid compound
EP1378502A4 (de) Kettenförmiger oligomilchsäureester
MXPA03011647A (es) Procedimiento de resolucion para el acido ( r ) - (-) - 2-hidroxi - 2- (2 - clorofenil) acetico.
EE05136B1 (et) Asendatud imidasopridiinhendite valmistamise meetod
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
FI20022159A0 (fi) Uusia farmaseuttisia yhdisteitä
CY1108381T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξαπενεμο-3-καρβοξυλικα οξεα
MY141657A (en) Novel intermediate for the preparation of therapeutically active imidazopyridines
AU2003248059A1 (en) NOVEL Alpha-KETOAMIDE DERIVATIVE AND USE THEREOF
TH65066A (th) อนุพันธ์พิร์โรโลพิริดิโนน ซึ่งถูกแทนที่ซึ่งมีประโยชน์เป็นตัวยับยั้งฟอสโฟไดเอสเทอเรส
TH65070A (de)